Home
KBP Biosciences

KBP Biosciences Market Share Analysis for July 2026

Industry: N/A

Domainkbpbiosciences.com

Year Founded2011

Employees51 - 200

Annual Revenue$25M - $50M

KBP Biosciences

KBP Biosciences (including company regionals)

kbpbiosciences.com

See more website traffic and engagement information

KBP Biosciences Revenue up to July 2026 is 25M - 50M

revenue generated by KBP Biosciences top domains

KBP Biosciences top domains revenue over 3 years

Revenue for KBP Biosciences top domains

kbpbiosciences.com25M - 50M

See more with Sales Intelligence

Total visits to KBP Biosciences's top domains

Understand KBP Biosciences market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kbpbiosciences.com669

See more with Sales Intelligence

Avg. visit duration in KBP Biosciences's top domains

Analyze KBP Biosciences engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kbpbiosciences.com00:00:38

See more with Sales Intelligence

Avg. pageviews on KBP Biosciences's top domains

See how KBP Biosciences keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kbpbiosciences.com1.73

See more with Sales Intelligence

KBP Biosciences top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by KBP Biosciences

These are the website technologies, by industry, used by KBP Biosciences top domains

Content Management System (2)

WordPress

Business Solutions (1)

DocuSign

eCommerce (1)

Swap

Email Services (1)

Microsoft Exchange Online

More Technologies

4

See all

News & Signals from KBP Biosciences

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNovo Nordisk A/S filed suit against KBP Biosciences PTE., Ltd. on Jul 8th '26.Novo Nordisk has quickly struck back in the legal dispute with the biotech company KBP Biosciences from Singapore.

NewsKBP Biosciences Inc has issues with failing to disclose crucial information.According to the latest report from The Star, KBP Biosciences, founded by Huang Zhenhua, is accused of failing to disclose crucial information about ocedurenone's clinical trial results, leading Novo to believe the drug was an effective treatment for hypertension and kidney disease.

NewsKBP Biosciences Inc sold assets to Novo Nordisk A/S in the amount of $1.3B on Jan 1st '23.Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences.